2015
DOI: 10.1038/nchembio.1776
|View full text |Cite
|
Sign up to set email alerts
|

Regulation of the oncoprotein Smoothened by small molecules

Abstract: The Hedgehog pathway is critical for animal development and has been implicated in multiple human malignancies. Despite great interest in targeting the pathway pharmacologically, many of the principles underlying the signal transduction cascade remain poorly understood. Hedgehog ligands are recognized by a unique receptor system that features the transporter-like protein Patched and the G protein-coupled receptor (GPCR)-like Smoothened (SMO). The biochemical interaction between these transmembrane proteins is … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
99
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 108 publications
(100 citation statements)
references
References 99 publications
(123 reference statements)
1
99
0
Order By: Relevance
“…Of note is that Tyr106 is also conserved within smoothened (SMO; Tyr103 in SMO), a hedgehog pathway receptor that contains an extracellular FZD-like CRD and is distantly related to the FZD family (SI Appendix, Fig. S1A) (26). In the crystal structure of SMO CRD, Tyr103 forms a hydrogen bond with the hydroxyl group of 20 (S)-hydroxycholesterol (27).…”
Section: Resultsmentioning
confidence: 99%
“…Of note is that Tyr106 is also conserved within smoothened (SMO; Tyr103 in SMO), a hedgehog pathway receptor that contains an extracellular FZD-like CRD and is distantly related to the FZD family (SI Appendix, Fig. S1A) (26). In the crystal structure of SMO CRD, Tyr103 forms a hydrogen bond with the hydroxyl group of 20 (S)-hydroxycholesterol (27).…”
Section: Resultsmentioning
confidence: 99%
“…Neither of the two distinct sites on Smo that are known to bind modulatory lipids, however, is likely to respond to Patched regulation. The extracellular CRD domain of Smoothened is not required for Patched action (18), and mutations affecting the cyclopamine pocket generally fail to disrupt regulation by Patched (15), suggesting that the Smoothened site responding to Patched regulation remains unknown, as does the identity of the molecule(s) that mediate this regulation. We therefore undertook an unbiased search for possible mediators of Smoothened regulation, using a cultured cell reporter assay to identify activities from various lipid extracts.…”
Section: Discussionmentioning
confidence: 99%
“…Several small molecules including cyclopamine derivatives and other synthetic compounds that have been characterized as inhibiting Smoothened by binding to the "cyclopamine pocket" are in clinical trials or have been approved for use as anticancer drugs (17). Recent structural studies define the cyclopamine pocket in atomic detail, but mutations affecting this pocket generally fail to disrupt regulation by Patched (15), suggesting a distinct site of action for an endogenous mediator of Patched regulation.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…14 These efforts have led to the identification of several potent inhibitors of GPCR-like Smoothened (Smo) receptor. 14 These include cyclopamine 15 and vismodegib 16 , which correspond to the archetypal member and the first FDA-approved drug, respectively, belonging to this class of Hh pathway antagonists. Compounds that target downstream components of this pathway 14 or processes involved in Shh maturation 17 have also been reported.…”
mentioning
confidence: 99%